Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction.

about

Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.

P2860

Q36384453-0573AF6C-A98F-444C-AF70-F423A44C58E5

P2860

Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction.

Item

http://www.wikidata.org/entity/Q35799000

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Angiotensin II receptor blocke ...... ular and renal risk reduction.

@ast

Angiotensin II receptor blocke ...... ular and renal risk reduction.

@en

type

Item

label

Angiotensin II receptor blocke ...... ular and renal risk reduction.

@ast

Angiotensin II receptor blocke ...... ular and renal risk reduction.

@en

prefLabel

Angiotensin II receptor blocke ...... ular and renal risk reduction.

@ast

Angiotensin II receptor blocke ...... ular and renal risk reduction.

@en

P1476

Angiotensin II receptor blocke ...... ular and renal risk reduction.

@en

P2093

Matthew R Weir

http://www.w3.org/2001/XMLSchema#string

P2860

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Comparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the A

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

The renin-angiotensin-aldosterone system: a specific target for hypertension management.

Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?

Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers.

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

P304

315-23; quiz 324-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1524-6175.2006.03473.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8518796

http://www.w3.org/2001/XMLSchema#string

P698

15187494

http://www.w3.org/2001/XMLSchema#string

Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction.

about

P2860

P2860

Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698